



**February 04, 2026**

**Ref:- GH/2025-26/EXCH/100**

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrip Code: 543654**

**Symbol: MEDANTA**

**Sub: Investor Presentation**

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the third quarter and nine-months ended December 31, 2025 Results.

Kindly take the above on record.


Thanking you,

Yours faithfully

**For Global Health Limited**

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**

**Encl: a/a**





# GLOBAL HEALTH LIMITED

Dedicated to Life

Investor Presentation

Q3 and 9M FY2026

4<sup>th</sup> February, 2026



- This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.
- These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.

# Contents

- 01 Q3 and 9M FY2026 Performance Update

---
- 02 Project Update and Capex Plan

---
- 03 Medanta's Journey, Purpose and Model of Healthcare

---
- 04 Annexures

---

01

# **Q3 and 9M FY2026 Performance Update**

# Q3 FY2026 performance summary

Strong quarter with Revenue Growth of 19% y-o-y and EBITDA ex Noida growth of 11% y-o-y

Total Income <sup>1</sup>		EBITDA <sup>3</sup> and Margins				Profit after Tax and Margins			
		EBITDA <sup>2</sup> ex Noida		Reported EBITDA		Adjusted PAT <sup>4</sup>		Reported PAT	
INR 11,428 million		INR 2,814 million Margin: 25.4%		INR 2,494 million Margin: 21.8%		INR 1,224 million Margin: 10.7%		INR 950 million Margin: 8.3%	
Q3 FY25	▲	Q3 FY25	▲	Q3 FY25	▼	Q3 FY25	▼	Q3 FY25	▼
9,595 million	19.1%	2,538 million Margin: 26.5%	10.9%	2,538 million Margin: 26.5%	-1.7%	1,429 million Margin: 14.9%	-14.3%	1,429 million Margin: 14.9%	-33.5%

Occupied Bed Days		ARPOB* (INR)		ALOS (days)		Patient Footfalls	
154,917		67,361		3.02		51,275 In-patients	861,000 Out-patients
Q3 FY25	▲	Q3 FY25	▲	Q3 FY25	▼	▲	▲
145,095	6.8%	61,307	9.9%	3.23	-6.6%	14.3%	19.5%
						Q3 FY25	Q3 FY25
						44,856	7,20,305

- 1. Noida generated Total Income of INR 343 million in Q3 FY26
- 2. Noida facility resulted in EBITDA loss of INR 320 million during the quarter
- 3. EBITDA represents EBITDA before ESOP expenses
- 4. Statutory impact of new Labour Codes is non-recurring in nature and classified as Exceptional Items amounting to INR 366 million in Q3 FY26

\*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days  
\*\* Outpatients volume reflects OPD encounters  
\*\*\*Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include Lucknow Unit. Accordingly all comparative period also include Lucknow unit numbers

# Q3 FY2026 performance summary

## Revenue growth of 19% y-o-y, primarily led by increase in patient volumes and realization

- Total Income was INR 11,428 million, up by 19.1 % y-o-y
- EBITDA (ex-Noida) was INR 2,814 million, up by 10.9 % y-o-y, with margins of 25.4%
- EBITDA Including Noida, was INR 2,494 million, down by 1.7% y-o-y, with margins at 21.8%
- Medanta Noida commenced operations in September 2025. The hospital generated revenue of INR 343 million and reported an EBITDA loss of INR 320 million in Q3 FY26
- Profit After Tax was INR 950 million. PAT was impacted by Noida hospital depreciation and finance cost in addition to initial operating losses. Additionally, PAT was further impacted due to statutory impact of new Labour Codes which is non-recurring in nature and classified as exceptional Items amounting to INR 366 million in Q3 FY26
- Total 144 beds were added in Q3 FY26, consisting of 42 beds at Patna and 102 bed at Noida hospital
- Volume growth remained robust, In-patient count up by 14.3% and Out-patient count up by 19.5% y-o-y
- ALOS was 3.02 days, an improvement of 6.6% y-o-y, Occupied bed days up by 6.8% y-o-y, representing an occupancy of ~59% on increased bed capacity
- ARPOB was INR 67,361, up by 9.9% y-o-y, driven by improvement in ALOS and change in case mix
- Matured hospitals revenue was INR 7,020 million, up by 9.4% y-o-y. EBITDA was INR 1,675 million, up by 6.7% y-o-y with margins of 23.9%
- Developing hospitals ex Noida, Revenue was INR 3,651 million, strong growth of 21.5% y-o-y. EBITDA was INR 1,156 million, up by 13.3% y-o-y with margins of 31.7%
- International Patients Revenue was INR 703 million, up by 29.9% y-o-y, driven by increased international patient volume
- OPD Pharmacy continues to register strong double digit growth. Revenue was INR 465 million, up by 30.3% y-o-y



# Q3 FY2026 business update

144 beds added in Q3 FY26 and deploying latest medical technologies to deliver clinical excellence



## Capacity Expansion

- ✓ **Group:** Total of 144 beds added in Q3 FY26. Total 537 beds addition in 9M FY26
- ✓ **Patna:** Total of 42 beds added in Q3 FY26. Total 99 bed addition in 9M FY26
- ✓ **Noida:** 102 beds added in Noida, taking total bed capacity to 328 in Q3 FY2026. 9 New OTs were operationalized during the quarter



## Attract Best Talent

- ✓ **110 Doctors on-boarded in** Q3 FY26 across Medanta network hospitals
- ✓ **70+ doctors;** on-boarded in Noida during the quarter
- ✓ **Major on-boarding is across** key clinical departments such as Cardiac, Critical Care and Cancer



## New Medical Equipment Deployed in Q3 FY26



**5<sup>th</sup> Radiation Oncology Machine Operationalized in Gurugram**



## Continuity of Care

- ✓ **25+** collection centres added in Q3 FY2026, taking collections centre to ~300+
- ✓ **19 operational pharmacy** comprising of, 7 Pharmacies in the Hospital, 2 Mediclinics and 10 Retail Pharmacies



# Medanta Noida fully operational with 300+beds

Formally inaugurated on 27<sup>th</sup> November, 2025. 328 beds and 14 OTs were operational at the end of Q3 FY26

## Medanta Noida Overview

<b>550+</b> Planned beds capacity	<b>328</b> Operational beds
<b>200+</b> Experienced Doctors	<b>36</b> Directors
<b>60+</b> Senior clinicians	<b>25+</b> Super Speciality
<b>450+</b> Nurses and paramedics	<b>1,200+</b> Full-time employees



Key metrics	1 Sept 2025	30 Sept 2025	Q3 FY2026
Total Census Bed	73	141	187
Daycare Beds	25	85	141
Total Bed Capacity	98	226	328
No. of OT's	5	5	14

# Latest advanced technology deployed at Noida

Providing the latest tools to enable our doctors to deliver the greatest care

**O-arm O2 Surgical  
Imaging System**



**SOMATOM Pro.  
Pulse  
Dual Source CT**



**ARTIS icono BiPlane  
CATH Lab**



**MAGNETOM Lumina  
3T MRI**



**ARTIS icono Ceiling  
with Abbott EP  
System – CATH Lab**



**Lumenis  
Pulse 100H Holmium  
Laser**



**ACUPULSE DUO CO2  
Laser System**

**Stealth Station S8  
Neuro Navigation  
System**



**Da Vinci Xi Robotic  
System**




**Leica Arveo 8 Digital  
Visulisation  
Microscope for  
Neurosurgery**




# Key operating metrics: Revenue and profitability

In 9M FY26 Total Income and EBITDA, excluding Noida, grew by 16% y-o-y

## Total Income (INR million)



## EBITDA<sup>1</sup> (INR million and margin %)




1. EBITDA represents EBITDA before ESOP Expenses


# Key operating metrics: Revenue and profitability

PBT growth on a y-o-y basis for both the nine months and the quarter was impacted by higher depreciation arising from the Noida hospital, along with increased non-cash expenses related to ESOPs.

## Profit before tax (INR million and margin %)



## Profit after tax (INR million and margin %)



\* Statutory impact of new Labour Codes is non-recurring in nature and classified as Exceptional Items amounting to INR 366 million in Q3 FY26


### Notes:

1. In Q2 FY26, Company reversed stamp duty payable on account of the merger of MHPL with GHL, amounting to Rs. 159.85 millions, pursuant to adjudication of its stamp duty application
2. In Q1 FY26, PAT is higher due to non-recurring exceptional income of Rs. 196 million arising due to reversal of potential interest liability on EPCG following transfer of EPCG licenses from MHPL to GHL.
3. Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include Lucknow Unit. Accordingly all comparative period also include Lucknow unit numbers


# Key operating metrics: Volumes, occupancies, ALOS

Occupied bed days grew by 7%, driven by in-patient volume growth of 14% y-o-y; ALOS improvement of 6%, occupancy of 59% on increased bed capacity


## Average census and occupied beds per day




## ALOS (days)



## IPD volumes




## OPD volumes\*




# Key operating metrics: ARPOB and revenue mix

ARPOB growth driven by improvement in ALOS and change in specialty mix


ARPOB\* (INR)




IPD Revenue mix by payor category\*\*



Domestic and international revenue breakdown



IPD vs OPD revenue breakdown




\*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

\*\* IPD Revenue mix is by payment type

# Diverse revenue<sup>1</sup> mix

## Significant contribution from complex specialties



### Notes:

1. Revenue from healthcare services excludes pharmacy revenue and other income
2. Revenue breakdowns are provided as per internal MIS at the Company's consolidated level
3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery




# 9M FY2026: Matured portfolio registered steady growth


## Growth in matured hospitals led by volume and case mix change

### Matured hospitals - Over 6 years


Total Income (INR million)




EBITDA (INR million and margin %)




In-patient Volume (count)




ALOS (days)



Occupied Bed Days (count)



ARPOB\* (INR)




\*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

# 9M FY2026: Developing portfolio continues to register strong growth


Developing hospitals, ex Noida, registered robust Revenue and EBITDA growth in 9M FY2026

## Developing hospitals – Less than 6 years


Total Income (INR million)




EBITDA (INR million and margin %)




In-patient Volume (count)




ALOS (days)



Occupied Bed Days (count)



ARPOB\* (INR)



\*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

1. Noida generated Total Income of INR 343 million in Q3 FY26 and INR 382 million in 9M FY26
2. Noida facility resulted in EBITDA loss of INR 320 million in Q3 FY26 and INR 547 million in 9M FY26
3. EBITDA represents EBITDA before ESOP expenses

02

## **Project Update and Capex Plan**

# Delhi: Strengthening our presence in the region with a planned capacity of ~1,000 beds

## Expanding into the high-growth, densely populated micro markets of Northwest and South Delhi

### Super specialty hospital in North West Delhi



*\*The artistic image for illustration purpose only*

- Medanta has signed an Operations and Management Agreement with Society to operate and manage a **~750 bed super speciality hospital at Pitampura, New Delhi**
- **7-acre site in Pitampura**, with a total built-up area of 7.6 Lakh sq.ft excluding the basement
- The hospital is to be **jointly built** by Medanta and Society **over next ~4 years**, subject to necessary statutory and customary approvals
- Medanta is expected to incur a **project capex of ~Rs. 600 cr**, to be funded by a combination of internal accruals and debt financing
- **Architectural drawings submitted for approvals. Construction will commence upon receipt of the building permit, based on the drawings**

### Super specialty hospital in South Delhi



*The artistic image for illustration purposes only*

- **~400-bed super specialty** hospital in South Delhi
- DLF and Medanta will contribute equity in equal proportion (50:50)
- **Medanta will run the hospital** and have operational control; DLF will be a strategic investor
- SPV named **“GHL Hospital Limited”** was formed in December 2023
- Soil testing has been completed on site 1
- **Barricading has been completed. Diaphragm wall (D-wall) work is in progress on site 1**

# Medanta to enter Mumbai market with a state-of-the-art, 750+ bedded super-specialty hospital at Oshiwara, Mumbai



*\*The artistic image for illustration purpose only*

## Super specialty hospital in Oshiwara, Mumbai

- ✓ Approval for additional 4 FSI has been received and the requisite payment has been made in January 26. Total FSI available for the project is 5
- ✓ MMRDA approval for shoring and piling has been received
- ✓ The shoring and piling contract has been awarded
- ✓ Height clearance from the Airport Authority has been received
- ✓ Drawings have been submitted to the Chief Fire Officer for approval. Upon receipt, the same will be submitted to MAHADA for the planning permit
- ✓ This will be followed by applications for Environmental Clearance and approvals from BMC, post which the Commencement Certificate will be obtained



# Medanta to set up 400+ bedded super-specialty hospital in Guwahati

## 400+ Bedded Super specialty hospital in Guwahati



- ✓ Barricading Completed, soil testing complete. Consultant on-boarding in progress
- ✓ Temporary electricity connection approval received
- ✓ Planning permit received from the municipal authority
- ✓ Drawings submitted to Chief Fire Officer for approval
- ✓ Subsequently it will be submitted to municipal authority for NOC followed by Environment Clearance and CTE



# Completing the campus

## Establishing world class medical college and guest house for out of city patients

### Medanta Guest House



*\*The artistic image for illustration purposes only*

- **Medanta to construct a service apartments / guest house** on the “Medanta-The Medicity” Gurugram campus
- This project with an investment of ~Rs. 250 crores will cater to the growing demand from international as well as out of town domestic patients
- This facility will also help us optimize length of stay in our Gurugram hospital by providing continuity of care in a safe and secure out of hospital environment
- **D-wall and excavation completed. Civil Contractor on-boarded and pcc work complete, foundation work commenced**

### Medanta Medical College



*\*The artistic image for illustration purposes only*


- Establish a **world-class, future-ready Medical College** in Gurugram which would provide high quality education of global standards
- Documentation process of obtaining necessary regulatory approvals from the State and National Medical Council (NMC) has been initiated
- Architectural drawings are currently under preparation



# On-going expansion projects

Planned bed capacity addition; well positioned to drive near term growth


## Number of installed beds



- ❖ **Patna:** Total 42 beds added in Q3 FY2026 taking total bed addition to 99 beds in 9M FY2026
- ❖ **Ranchi:** Newly built 110 bedded hospital in Ranchi, operationalized in July 2025
- ❖ **Noida with total capacity of 550 beds:** Noida commenced operations with 226 beds in September, 2025, 102 beds added in Q3 FY26 taking total bed count to 328 beds at the end of December 2025
- ❖ **South Delhi:** Announced 400 bed in partnership with DLF. Site survey complete, soil testing complete. Construction is in progress on site 1
- ❖ **Pitampura, New Delhi:** Signed O&M Agreement to jointly build and operate and manage a ~750 bed hospital. Architectural drawings submitted
- ❖ **Mumbai:** Land acquired in Mumbai in October 2024. Additional FSI approval received. Building drawings submitted for approval
- ❖ **Guwahati, Assam:** Land acquisition and possession have been completed. Planning permit received, other approvals are in progress

# Capex plan next 5 years

— **Total capex of over ~INR 39,013 million planned for next 5 years**



- ❖ In 9M FY2026, **INR 6,246 million of capex incurred**
- ❖ **Maintenance capex estimated at INR ~4,500 million** to be incurred over next three years
- ❖ **Total Project capex estimated at INR ~34,513 million**, to be funded by combination of Debt funding and internal accruals

03

## **Medanta's Journey, Purpose and Model of Healthcare**

# Medanta was founded to bring a new type of healthcare to India...

## ... the human side of healthcare

Healthcare is never only about science. It is also about the **art of medicine** – the **human connection**, putting the **patient first**, **collaboration**, the personal acts of **empathy** and the **values** that guide our decision making.



At Medanta we have built an institution to match the highest benchmarks of excellence globally. We have created an ecosystem of excellence that encompasses world-leading clinicians, state-of-the-art equipment, best-in-class infrastructure, and a strong emphasis on research and innovation.


Medanta's patient-first approach allows teams of super-specialist doctors to collaborate seamlessly and arrive at the best-possible treatment customized for each patient in line with our guiding philosophy 'Har Ek Jaan Anmol', meaning 'Every Life is Invaluable'



**Dr. Naresh Trehan**  
**CMD & Chief Cardiac Surgeon, Medanta**

# Growth from a single flagship hospital in Gurgaon...

...to a network of 6 high quality hospitals across north India



\*Carlyle Group (Anant Investments) exited completely in the IPO

# From our flagship Medicity campus in Gurgaon, we have grown to ~3,550+ beds across 6 cities

## Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar



### **Gurgaon**

1,440 beds; 316 ICU beds



### **LUCKNOW**

757 beds; 202 ICU beds (950 planned)



### **PATNA**

569 beds; 147 ICU beds (650 planned)



### **INDORE**

175 beds; 53 ICU beds



### **RANCHI\***

310 beds; 102 ICU beds




### **NOIDA**

328 beds; 81 ICU beds (550 planned)

# One of the largest private hospital chains in North and East India



Serving over 400 million people in the States with Medanta facilities



## Our Network

Hospital Network	Bed Capacity	Infrastructure
6 Multi-speciality hospitals	3,579 Total Beds	900+ ICU Beds
4 Upcoming hospitals	~2,300+ Planned Bed Addition	90+ Operating Theatres

## Continuity of care

Medanta Clinics	Medanta Labs	Pharmacy
8 Clinics	12 Labs total	19 Pharmacy
5 cities	310+ Collection centre	10 Retail

## Our People

Doctors	Nurses and paramedics	Full-time and retainer employees
2,300+	8,250	14,000+



## Embracing a new era and redefining our purpose

### MISSION

Our mission is to deliver world class, patient centric, integrated and affordable healthcare through a dynamic institution that focuses on the development of people and knowledge

#### Core Values



**Patient centric care:** Foster a culture where every one of us is committed to care for patients and their caregivers



**Leadership and quality:** Commit to delivering excellence in everything we do through exemplary action and behaviour




**Integrity and courage:** Maintain the highest ethical standards by putting the patient first and demonstrating the courage to do what is right



**Collaboration, learning and innovation:** Promote teamwork and collaboration, welcome change and creativity, encourage innovation

# The Medanta Model of Healthcare

Delivering the highest quality of medicine with care and compassion




## What it means for patients and caregivers?

- Super specialized doctors provide the highest quality of care through a team based integrated approach
- A safe and friendly healing environment with a patient-centric design in all clinical areas and public spaces
- Availability of the most advanced, innovative equipment and technology to enable the most complex diagnostics and treatment
- Doctors who take ownership and personal responsibility
- Respect-based processes for patients and their families

# Medanta is well placed to deliver sustainable growth...

...while maintaining its core values of patient centric care and clinical leadership and quality





## 04 **Annexures**

# Annexure: Profit and Loss Statement

INR million	Nine Months			Quarter			
	9M FY25	9M FY26	Y-o-Y Growth %	Q3 FY25	Q2 FY26	Q3 FY26	Y-o-Y Growth %
<b>Revenue from operations</b>	<b>27,611</b>	<b>32,511</b>	<b>17.7%</b>	<b>9,434</b>	<b>10,992</b>	<b>11,210</b>	<b>18.8%</b>
Other income	562	620	10.3%	160	197	218	35.9%
<b>Total income</b>	<b>28,172</b>	<b>33,131</b>	<b>17.6%</b>	<b>9,595</b>	<b>11,189</b>	<b>11,428</b>	<b>19.1%</b>
Cost of materials consumed	6,661	7,503	12.6%	2,292	2,556	2,557	11.5%
Employee benefits expense	9,862	12,543	27.2%	3,300	4,193	4,498	36.3%
Other expenses	4,564	5,432	19.0%	1,465	1,834	1,880	28.3%
<b>EBITDA</b>	<b>7,085</b>	<b>7,654</b>	<b>8.0%</b>	<b>2,538</b>	<b>2,607</b>	<b>2,494</b>	<b>(1.7)%</b>
<b>EBITDA Margins %</b>	<b>25.2%</b>	<b>23.1%</b>	<b>(205) bps</b>	<b>26.5%</b>	<b>23.3%</b>	<b>21.8%</b>	<b>(463) bps</b>
ESOP Expenses	0	282	na	0	100	103	na
<b>EBITDA after ESOP Expenses</b>	<b>7,085</b>	<b>7,372</b>	<b>4.0%</b>	<b>2,538</b>	<b>2,507</b>	<b>2,391</b>	<b>(5.8)%</b>
Finance costs	502	524	4.3%	163	171	215	32.2%
Depreciation and amortisation expense	1,445	1,560	8.0%	484	497	612	26.3%
Exceptional item expense <sup>1</sup> (income)	0	10	na	0	(160)	366	na
<b>Profit before tax</b>	<b>5,138</b>	<b>5,277</b>	<b>2.7%</b>	<b>1,891</b>	<b>1,998</b>	<b>1,198</b>	<b>(36.6)%</b>
Tax expenses	1,339	1,153	(13.9)%	462	414	248	(46.4)%
<b>Profit after tax</b>	<b>3,799</b>	<b>4,124</b>	<b>8.5%</b>	<b>1,429</b>	<b>1,584</b>	<b>950</b>	<b>(33.5)%</b>

1. Statutory impact of new Labour Codes is non-recurring in nature and classified as Exceptional Items amounting to INR 366 million in Q3 FY26

In Q2 FY26, Company reversed stamp duty payable on account of the merger of MHPL with GHL, amounting to Rs. 159.85 millions, pursuant to adjudication of its stamp duty application  
 In Q1 FY26, PAT is higher due to non-recurring exceptional income of Rs. 196 million arising due to reversal of potential interest liability on EPCG following transfer of EPCG licenses from MHPL to GHL.  
 Pursuant to the merger of MHPL with GHL, the GHL standalone results for the reported period now include Lucknow Unit. Accordingly all comparative period also include Lucknow unit numbers

# Annexure: Operational Parameters

Key metrics	Year End			Quarter				
	9M FY25	9M FY26	Y-o-Y Growth %	Q3 FY25	Q2 FY26	Q3 FY26	Y-o-Y Growth %	Q-o-Q Growth %
Total Beds	3,042	<b>3,579</b>	17.7%	3,042	3,435	<b>3,579</b>	17.7%	4.2%
Census Beds	2,427	<b>2,665</b>	9.8%	2,480	2,658	<b>2,851</b>	15.0%	7.3%
Occupied Bed Days	415,731	<b>453,544</b>	9.1%	145,095	155,729	<b>154,917</b>	6.8%	(0.5)%
Occupancy Rate %	62.3%	<b>61.9%</b>	(0.7)%	63.6%	63.7%	<b>59.1%</b>	(453),bps	(7.3)%
ARPOB (INR)*	62,424	<b>66,501</b>	6.5%	61,307	65,570	<b>67,361</b>	9.9%	2.7%
ALOS (days)	3.17	<b>3.04</b>	(4.1)%	3.23	3.06	<b>3.02</b>	(6.6)%	(1.2)%
In-Patient Volumes	131,318	<b>149,350</b>	13.7%	44,856	50,925	<b>51,275</b>	14.3%	0.7%
Out-Patient Volumes	2,219,392	<b>2,570,565</b>	15.8%	720,305	890,750	<b>861,000</b>	19.5%	(3.3)%

- Census Beds as based on monthly average during the period
- ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days
- Out-Patient volumes are sum of encounters at Out-Patient departments

## Abbreviations

- INR : Indian Rupee
- NABH : National Accreditation Board for Hospitals & Healthcare Providers
- NABL : National Accreditation Board for Testing and Calibration Laboratories
- JCI : Joint Commission International
- OPD : Out-Patient Department
- IPD : In Patient Department
- ICU : Intensive Care Unit
- Mn : Million
- ARPOB : Average Revenue Per Occupied Bed
- ALOS : Average Length of Stay
- EBITDA: EBITDA represents Profit before tax after adding back finance costs, ESOP expenses and depreciation and amortization of the relevant year/period
- EBITDA Margin : EBITDA divided by Total Income in percentage
- PAT : Profit After Tax
- NCR : National Capital Region

## Definitions

- Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other bed available other than census beds, i.e., day-care beds).
- Occupied beds : Total Count of patients at midnight at each day
- Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catheterization & Observation room
- ICU Beds: No of ICU Beds available in the hospital out of census beds
- Total Income : Revenue from Operations + Other Income
- ARPOB : Income from Health Care Services excluding Pharmacy and Other Income revenue divided by occupied bed days
- ALOS : Average number of days spent by admitted inpatients
- Revenue mix by Payment Type, i.e. Cash, TPA, CGHS, ECHS, PSU others.



## About Medanta

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited.

Under the “Medanta” brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,579 installed beds as on December 30, 2025. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 2,300+ doctors led by highly experienced department heads.

## Contact Details

**Ravi Gothwal –**  
Head of Investor Relations



+91 95996 55711



ravi.gothwal@medanta.org



### Corporate Office

#### **Medanta; The Medicity**

CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38,  
Gurgaon, Haryana 122001



**For further information, please visit our website:**

<https://www.medanta.org/>